Corporate Governance & Management team

Mr. Blondel is Founder and Executive Chairman of the Board of Directors of KiOmed Pharma.
He has acquired a broad experience in the management and the development of innovation driven companies. Having graduated in both Law and Economics, nowadays he combines executive functions (as CEO...

Mr. Blondel is Founder and Executive Chairman of the Board of Directors of KiOmed Pharma.
He has acquired a broad experience in the management and the development of innovation driven companies. Having graduated in both Law and Economics, nowadays he combines executive functions (as CEO of KitoZyme) with non-executive board memberships, either as Chairman of the Board or as an independant Board member. The companies in which he is, or has been, active range from SMEs, spin-offs and research centers, such as DELPHI GENETICS, OncoDNA, NANOCYL, CERTECH, KAZIDOMI, OVIZIO Imaging Systems, etc. which are active in the technology, medical, healthcare or digital sectors, to major listed companies, such as COMPAGNIE du BOIS SAUVAGE, RECTICEL or CASTERMAN/EVADIX.
Mr. Blondel started his career in the chemical sector and undertook assignments both in the United States and in Europe, for the French group TOTAL. In 1999, he joined International Brachytherapy (IBt), a medical device start-up that focused on cancer treatment. He served as CEO, leading IBt from its R&D stage to a successful and well-diversified international group that became a European leader in its market segment and a NYSE-Euronext stock listed company.

Dr. Choumane has been CEO and Managing Director of KiOmed Pharma since its inception in 2014.

He has acquired nearly 20 years’ experience in product development, executive management and business development of innovative biotech companies.
Dr. Choumane acquired...

Dr. Choumane has been CEO and Managing Director of KiOmed Pharma since its inception in 2014.

He has acquired nearly 20 years’ experience in product development, executive management and business development of innovative biotech companies.
Dr. Choumane acquired experience in osteoarthritis markets as former CEO of Artialis S.A (BE) (2012-2014), a first-mover biotech company that specialized in the development and the clinical applications of biomarkers for the diagnosis and prognosis of musculoskeletal disorders. As CEO, he drove and accelerated (2002-2010) value creation at Genewave (acquired by mobidiag https://mobidiag.com) a Paris-based development-stage diagnostics company that develops innovative molecular solutions to advance the diagnosis of infectious diseases and antibiotic resistances.
He has a highly diverse background that combines a technical element (he holds a PhD in Sciences) and business administration (he received an Executive MBA from HEC-Paris), as well as a Major in Innovation and Entrepreneurship from Babson College (MA, USA).

Benoît Fellin is an investment manager at Noshaq and director of WHITE fund. He is also a non-executive member of several biotech spin-offs and SMEs in the healthcare and industrial business sectors.

In 2003, he graduated in Business Administration at the University of Liège...

Benoît Fellin is an investment manager at Noshaq and director of WHITE fund. He is also a non-executive member of several biotech spin-offs and SMEs in the healthcare and industrial business sectors.

In 2003, he graduated in Business Administration at the University of Liège and started his career supporting entrepreneurs with the creation and development of early-stage projects. He decided to offer operational services to 2-3 customers (inter-CFO, strategic, and operational consulting).

In 2019, Benoît and one of his colleagues created WHITE FUND, a new private early stage investment fund based in Belgium, which is entirely dedicated to the medical device sector.

Caroline THIELEN is Investment Manager - Life Sciences at S.R.I.W. (Société Régionale d’Investissement de Wallonie) and Board Member of several biotech and medtech companies. Over the past 20 years, Caroline has gained solid experience in coordinating research projects at national and...

Caroline THIELEN is Investment Manager - Life Sciences at S.R.I.W. (Société Régionale d’Investissement de Wallonie) and Board Member of several biotech and medtech companies. Over the past 20 years, Caroline has gained solid experience in coordinating research projects at national and international levels. From 2013 to 2020, she has served as Chief Operating Officer of Bridge2Health, a major player in the development and reinforcement of the healthcare sector in connection with the academic research at ULiège and CHU de Liège. Caroline holds a Master’s degree in Biology and a PhD in Immunology from the University of Liège completed by a postdoctoral training at the Centers for Disease Control and Prevention (CDC, Atlanta, USA).

Mr. Nolet is Director of KiOmed Pharma.

Marc Nolet de Brauwere obtained his Master’s degree as a Mining Civil Engineer from the Catholic University of Louvain (UCL) in 1982, then specialized as a Civil Engineer in Industrial Management at the Katholiek Universiteit Leuven (KUL)...

Mr. Nolet is Director of KiOmed Pharma.

Marc Nolet de Brauwere obtained his Master’s degree as a Mining Civil Engineer from the Catholic University of Louvain (UCL) in 1982, then specialized as a Civil Engineer in Industrial Management at the Katholiek Universiteit Leuven (KUL) in 1983. He started his career in 1984, as Manager of the Engineering department at Petrofina (Kentucky Prince Coal Corporation). In 1978, he also took charge of the development of a downstream activity (gold mining) at Chemetech Corporation. He served for these two companies until 1989, then moved on to McKinsey & Company, as an Associate.

In 1992, Marc created Dat International SA with an ex-colleague of McKinsey, and set up a distribution network specialized in supply parts from the EEC to local companies in East Africa. Finally, in 1997, he became CEO of Physiol SA. Besides, he was nominated Director at ETEX group in 2003, where he served as chairman of the Audit committee from 2006 to 2013. He became Chairman of the Nominations and Remunerations Committee in 2013. In addition, he became Director of Mecatech (2011), Biotech Coaching (2011), MyMicroInvest (2013) and EndoTools Therapeutics (2013). Since 2011 he also is a member of Ashoka Support Network since 2011.

Dr. Choumane has been CEO and Managing Director of KiOmed Pharma since its inception in 2014.

He has acquired nearly 20 years’ experience in product development, executive management and business development of innovative biotech companies.
Dr. Choumane acquired...

Dr. Choumane has been CEO and Managing Director of KiOmed Pharma since its inception in 2014.

He has acquired nearly 20 years’ experience in product development, executive management and business development of innovative biotech companies.
Dr. Choumane acquired experience in osteoarthritis markets as former CEO of Artialis S.A (BE) (2012-2014), a first-mover biotech company that specialized in the development and the clinical applications of biomarkers for the diagnosis and prognosis of musculoskeletal disorders. As CEO, he drove and accelerated (2002-2010) value creation at Genewave (acquired by mobidiag https://mobidiag.com) a Paris-based development-stage diagnostics company that develops innovative molecular solutions to advance the diagnosis of infectious diseases and antibiotic resistances.
He has a highly diverse background that combines a technical element (he holds a PhD in Sciences) and business administration (he received an Executive MBA from HEC-Paris), as well as a Major in Innovation and Entrepreneurship from Babson College (MA, USA).

Bertrand Duquesne, Chief Operating Officer is working for KiOmed Pharma since January 2022, holding a master's degree in pharmaceutical sciences from the Université Catholique de Louvain. Before joining KiOmed Pharma, Bertrand was CEO and pharmaceutical qualified person for the Belgian and...

Bertrand Duquesne, Chief Operating Officer is working for KiOmed Pharma since January 2022, holding a master's degree in pharmaceutical sciences from the Université Catholique de Louvain. Before joining KiOmed Pharma, Bertrand was CEO and pharmaceutical qualified person for the Belgian and Luxembourg activities of the Boiron group, world leader in homeopathy.

He is an industrial pharmacist (QP/RIP agreement), with 18 years of experience in quality management (GDP, GMP and cGMP), production and in business management. He is in charge of industrial strategy (Extension, Scale Up and/or GMP) and supervises the operational organization. He manages the company's transversal projects, production, quality, HR and regulatory activities.

Arnaud Loriers, Chief Business Officer Ophthalmology is working for KiOmed Pharma since June 2022. Graduated in Business Administration at ICHEC, he started his career in finance, cost control and audit in international corporations 20 years ago, he discovered the pharma world which became a...

Arnaud Loriers, Chief Business Officer Ophthalmology is working for KiOmed Pharma since June 2022. Graduated in Business Administration at ICHEC, he started his career in finance, cost control and audit in international corporations 20 years ago, he discovered the pharma world which became a real passion.

Since then he has acquired a broad experience at both national and international levels in several commercial and business management roles with a strong track record of market development & launches, pricing & tenders, commercial excellence & customer engagement and organization development in several therapeutic areas including vaccines, oncology, ophthalmology, cardiology, neurology and rare diseases.

Franck VILLAIN is Chief Development Officer for Aesthetic Dermatology. He holds a PhD in Polymer Chemistry. He has about 30 years of experience in the Medical Device Industry in the development of product or in Medical Affairs. He has a 28-year experience in hyaluronan and polysaccharides. He...

Franck VILLAIN is Chief Development Officer for Aesthetic Dermatology. He holds a PhD in Polymer Chemistry. He has about 30 years of experience in the Medical Device Industry in the development of product or in Medical Affairs. He has a 28-year experience in hyaluronan and polysaccharides. He worked mainly in three fields aesthetic dermatology, ophthalmology, and rheumatology.

Finance director for KiOmed Pharma since 2021. Quentin has more than 15 years of experience in corporate finance across various sectors, including biotech, retail and industry, having served in operational roles as well as a consultant.

Michael O’Regan, Ph.D., Chief Business Officer OsteoArticular, is a seasoned Life Sciences executive with 25 years experience in a range of Biotech, Pharma and Med Tech organizations where he has focused on bridging the gap between technology and the marketplace.